This document summarizes the STOP ACEi trial, which investigated whether continuing or discontinuing renin-angiotensin system (RAS) inhibitors impacted kidney function decline in patients with advanced chronic kidney disease (CKD). The trial randomized 411 patients with CKD stages 4-5 to either continue or discontinue their RAS inhibitor treatment. The primary outcome was estimated glomerular filtration rate (eGFR) after 3 years, with secondary outcomes including time to end-stage kidney disease and hospitalization rates. The results showed no improvement in kidney function for those who discontinued RAS inhibitors. The authors concluded that stopping RAS inhibitors in advanced CKD does not provide benefit and may be harmful.
Presentation given to our fellowship program about diabetic kidney disease.
2022 update discussing SGLT2i, MRA (e.g. finerenone), health economics and beyond
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. GawadNephroTube - Dr.Gawad
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/kanEHVsStsI
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Linking HFpEF and Chronic kidney disease magdy elmasry
Cardio-renal interactions
Introducing nephro-cardiology
{ or cardio-nephrology }
Where are we in 2022 with HFpEF ?CKD in HFpEF { or HFpEF in CKD } Cardiorenal
Syndrome .Four-step
HFA-PEFF diagnostic algorithm
heterogeneity in patients with HFpEF.Phenotyping HFpEF :
Beyond EF.Management of HFpEF .patients with HF on dialysis
Cardio-Renal Protection Through Renin–Angiotensin–Aldosterone System Inhibitionmagdy elmasry
Physiological and detrimental roles of RAAS molecules in cardiac, vascular tissues and kidneys.‘cardiovascular continuum’ Barriers In Optimizing RAAS Inhibition.The effects of angiotensin II inhibition and improvement in bradykinin availability
Presentation given to our fellowship program about diabetic kidney disease.
2022 update discussing SGLT2i, MRA (e.g. finerenone), health economics and beyond
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. GawadNephroTube - Dr.Gawad
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/kanEHVsStsI
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Linking HFpEF and Chronic kidney disease magdy elmasry
Cardio-renal interactions
Introducing nephro-cardiology
{ or cardio-nephrology }
Where are we in 2022 with HFpEF ?CKD in HFpEF { or HFpEF in CKD } Cardiorenal
Syndrome .Four-step
HFA-PEFF diagnostic algorithm
heterogeneity in patients with HFpEF.Phenotyping HFpEF :
Beyond EF.Management of HFpEF .patients with HF on dialysis
Cardio-Renal Protection Through Renin–Angiotensin–Aldosterone System Inhibitionmagdy elmasry
Physiological and detrimental roles of RAAS molecules in cardiac, vascular tissues and kidneys.‘cardiovascular continuum’ Barriers In Optimizing RAAS Inhibition.The effects of angiotensin II inhibition and improvement in bradykinin availability
Recent Advancements in the treatment of Hypertension.Akshata Darandale
Uncontrolled blood pressure had become most common cause of death accounting for more than 7 million deaths per year worldwide. Despite the availability of potent lifestyle and pharmacologic approaches, rates of control of blood pressure are unsatisfactory and additional strategies to curb the burden of hypertension are warranted. Several novel pharmacological and device-based approaches have recently been tested and may prove helpful to achieve better blood pressure control rates and thereby improve cardiovascular outcomes in patients with hypertension.
New class of therapeutic agents called soluble guanylate cyclase (sGC) stimulators.
Impairment of NO synthesis and signaling through the NO-sGC–cGMP pathway is involved in the pathogenesis of pulmonary hypertension.
Dual mode of action,
Directly stimulating sGC independently of NO, and
Increasing the sensitivity of sGC to NO.
vasorelaxation , antiproliferative and antifibrotic effects
Drugs for prophylaxis of Myocardial InfarctionJervinM
Drugs for prophylaxis of Myocardial Infarction
Myocardial Infarction
Drugs for primary prevention of MI
Drugs for secondary prevention of MI
Recent advances
Cardiac rehabilitation
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
1. Presenter: Mohamed Hufane (R1/1M)
Moderator: Abdul-Aziz, MD (consultant internist)
THE STOP ACEI TRIAL
RENIN–ANGIOTENSIN
SYSTEM INHIBITION IN
ADVANCED CHRONIC
KIDNEY DISEASE
2.
3. PREVIOUS TRIALS
Lewis et al
2001
• The angiotensin-II-
receptor blocker
irbesartan is effective in
protecting against the
progression of
nephropathy due to type
2 diabetes. This
protection is independent
of the reduction in blood
pressure it causes.
Lancet
1997
• In chronic nephropathies
with proteinuria of 3 g or
more per 24 h, ramipril
safely reduces
proteinuria and the rate
of GFR decline to an
extent that seems to
exceed the reduction
expected for the degree
of blood-pressure
lowering.
Jafar et al
2001
• The beneficial effect of
ACE inhibitors is
mediated by factors in
addition to decreasing
blood pressure and
urinary protein excretion
and is greater in patients
with proteinuria.
• Bateman E et al. NEJM. 2018;378(20):1877-1887.
5. TRIAL DESIGN
• STOP ACEi was a multi-center, randomized, open-label trial that
examined the impact of continuation of RAS inhibitors on the
eGFR in advanced CKD.
• Patients were enrolled at 39 centers in the United Kingdom.
• RAS inhibitors were defined as ACEi or ARB
• 17,290 patients screened between July 11, 2014, and June 19,
2018. Of these, 1,210 patients were invited to participate, and
411 patients (from 37 centers) were randomized.
6. POPULATION
Inclusion Criteria
• Adults >18 years old
• CKD Stage 4-5 (eGFR < 30 ml/min/1.73m2)
• Decrease in eGFR >2 ml/min/1.73m2 per year in the previous 2 years
• Receiving treatment with an ACEi, ARB or both for > 6 months
7. Exclusion Criteria
• Receiving dialysis
• Having had a kidney transplant
• Uncontrolled hypertension (BP > 160/90 mmHg)
• Immune mediated kidney disease requiring specific
therapy
• MI or stroke within the previous 3 months
8.
9.
10.
11. INTERVENTIONS
• Randomized in a 1:1
• RAS continue group
• No RAS continue group
• Both groups were allowed to have any guideline-
recommended antihypertensive added to their regimens to
meet the study blood pressure target of <140/85 mmHg,
including MRAs (which also inhibit RAS via
mineralocorticoid receptor antagonism).
• Patients in the discontinuation group were not to resume
ACEi or ARB unless all other options were ineffective or
associated with intolerable side effects.
• Participants were followed every 3 months after
randomization for a total period of 3 years.
12. OUTCOMES
Primary endoints
• The eGFR at 3-years follow-up calculated using the 4-variable
MDRD175 equation was the primary end-point.
• They also repeated the primary analysis using the CKD-EPI
2009 equation and the MDRD186 equation
13.
14.
15. Secondary endpoints
• Time to development of ESKD (defined by the local investigator,
with criteria including palliative care and RRT)
• Composite including decrease in eGFR > 50%, development of
ESKD and initiation of KRT
• Any cause hospitalization
• Blood pressure measures
• Quality of life (Kidney Disease Quality of Life 36-Item Short Form
Survey, version 1.3)
• Exercise capacity (6-minute walk test)
• CVD events
• Death
• Hemoglobin
• Urinary Protein-to-creatinine Ratio (uPCR)
16.
17.
18. STRENGHTS
• Good trial design
• Good monitoring and follow up.
• Even representation of different
etiologies of CKD
• Authors did not include dosing
information for the RAS inhibitors
• The open-label nature of this
study may have contributed to
bias, particularly with respect to
subjective endpoints (e.g. quality-
of-life).
WEAKNESSES
CRITICISM
20. AUTHOR’S
CONCLUSIONS
• The results of this trial confirm that
discontinuation of ACEi or ARB in
patients with advanced CKD does
not provide meaningful
improvement of kidney function.
• A knee jerk response of stopping
RAS inhibitors in advanced CKD at
an arbitrary GFR threshold is
incorrect.
Beasley RD et al. NEJM. 2019; 380(21):2020-
2030.